The expert panel concludes its discussion with a focus on the future of MRD testing in colorectal cancer, highlighting the treatment landscape’s current strengths and challenges.
FDA Approves Noninvasive Stool RNA Test for Colorectal Cancer Screening
Data from the phase 3 CRC-PREVENT trial support the sensitivity of ColoSense in the detection of colorectal cancer.
Joleen Hubbard, MD, Highlights The “Exciting Space” Of Metastatic CRC
New studies and treatment options prove to be effective in treating metastatic CRC, notes Joleen Hubbard, MD.
ME-344/Bevacizumab Combo Shows Early Efficacy in mCRC
ME-344 and bevacizumab can now have an additional 20 patients enrolled on the phase 1b trial for relapsed metastatic colorectal cancer.
Tanios S. Bekaii-Saab, MD, Speaks to Expanding Horizons in CRC Treatment
Personalized therapy tailored for mutation status is something to expect in the coming years for colorectal cancer treatment, notes Tanios S. Bekaii-Saab, MD.
Adagrasib Combo Yields Encouraging Responses in KRAS G12C–Mutated CRC
Data from the phase 1/2 KRYSTAL-1 trial may support adagrasib plus cetuximab as a new standard in previously treated metastatic KRAS G12C–mutated CRC.
Blood-Based Test May Help Detect CRC in Average-Risk Population
The PREEMPT trial analyzed samples from 27,010 average-risk adults to determine the specificity of detecting colorectal cancer.